… hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary
fibrosis risk, we investigated whether distinct pharmacotherapies (amiodarone, cancer …

… Background: Pulmonary fibrosis (PF) is characterized by lung … occurs following hospitalization
for SARS-CoV-2 infection. … PF risk, we investigated whether distinct pharmacotherapies (…

… SARS-CoV-2 infection: a prospective nationwide cohort study in the United States. … exposure
increased the risk of post-COVID pulmonary fibrosis in part by increasing the risk of severe …

… We know about the role of SARSCoV-2 in PF development, but little is known about …
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide …

… Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective
nationwide … incidence and risk of pulmonary fibrosis caused by Pharmacotherapy. Recognizing …

… , using low dosages and decreasing the risk of toxicity. … of pirfenidone in pulmonary fibrosis
induced by SARS-CoV-2 is still … have therapeutic potential to prevent or reduce fibrotic lung …

… They performed a nationwide cohort study in the USA to … It is considered that the risk of
etanercept-induced lung injury is … onset of lung symptoms was 14 months after pharmacotherapy …

… pulmonary fibrosis and cytokine storm, which leads to failure of … as a severe risk for
SARS-CoV-2 infection. Adipocytes act as … the prospective role of being overweight as a risk factor …

… lung diseases (ILDs) such as IPF and LAM have elevated ACE2, TMPRSS2, and Furin levels,
increasing their risk for SARS-CoV-2 infection and … is also a potential risk factor for severe …

… of pulmonary fibrosis. The data in this study also provide a … network pharmacology analysis
between ARND and SARS-CoV-2 … In a nationwide study performed in Korea, allergic rhinitis …